MonTa Biosciences ApS - CVR: 36697016

2023, DKK

15.05.2024

Bruttoresultat

2.025'

Primær drift

-1.749'

Årets resultat

-3.279'

Aktiver

73.387'

Kortfristede aktiver

15.270'

Egenkapital

-1.607'

Afkastningsgrad

-2 %

Soliditetsgrad

-2 %

Likviditetsgrad

+500%

Resultat

15.05.2024

Årsrapport	2023 15.05.2024	2022 14.04.2023	2021 19.04.2022	2020 12.04.2021
Nettoomsætning
Bruttoresultat	2.024.634	1.756.938	2.130.489	-13.309.779
Resultat af primær drift	-1.749.104	-1.324.719	-1.318.070	-15.654.947
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0
Finansielle indtægter	10.244	0	0	0
Finansieringsomkostninger	-2.841.464	-1.913.958	-1.294.517	-792.441
Andre finansielle omkostninger	0	0	0	0
Resultat før skat	-4.580.324	-3.238.677	-2.612.587	-16.447.388
Resultat	-3.278.626	-1.439.137	1.406.263	-13.292.779
Forslag til udbytte	0	0	0	0

Aktiver

15.05.2024

Årsrapport	2023 15.05.2024	2022 14.04.2023	2021 19.04.2022	2020 12.04.2021
Kortfristede varebeholdninger	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	2.097.712	3.820.958	8.375.208	5.562.433
Likvider	13.172.008	4.009.930	1.793.471	5.293.456
Kortfristede aktiver	15.269.720	7.830.888	10.168.679	10.855.889
Immaterielle aktiver og goodwill	58.088.500	41.297.227	24.822.046	9.514.608
Finansielle anlægsaktiver	28.664	25.986	25.328	24.710
Materielle aktiver	0	0	0	0
Langfristede aktiver	58.117.164	41.323.213	24.847.374	9.539.318
Aktiver	73.386.884	49.154.101	35.016.053	20.395.207

Aktiver

15.05.2024

Passiver

15.05.2024

Årsrapport	2023 15.05.2024	2022 14.04.2023	2021 19.04.2022	2020 12.04.2021
Forslag til udbytte	0	0	0	0
Egenkapital	-1.607.124	1.671.502	3.110.639	1.704.376
Hensatte forpligtelser	3.842.000	3.267.000	1.442.000	2.093.214
Langfristet gæld til banker	0	0	0	0
Anden langfristet gæld		0	0	0
Leverandører af varer og tjenesteydelser	60.000	52.000	52.000	52.000
Kortfristede forpligtelser	488.857	388.339	539.167	911.316
Gældsforpligtelser	71.152.008	44.215.599	30.463.414	16.597.617
Forpligtelser	71.152.008	44.215.599	30.463.414	16.597.617
Passiver	73.386.884	49.154.101	35.016.053	20.395.207

Passiver

15.05.2024

Nøgletal

15.05.2024

Årsrapport	2023 15.05.2024	2022 14.04.2023	2021 19.04.2022	2020 12.04.2021
Afkastningsgrad	-2,4 %	-2,7 %	-3,8 %	-76,8 %
Dækningsgrad	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.
Egenkapitals-forretning	204,0 %	-86,1 %	45,2 %	-779,9 %
Payout-ratio	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-61,6 %	-69,2 %	-101,8 %	-1.975,5 %
Soliditestgrad	-2,2 %	3,4 %	8,9 %	8,4 %
Likviditetsgrad	3.123,6 %	2.016,5 %	1.886,0 %	1.191,2 %

Resultat

15.05.2024

Gæld

15.05.2024

Årsrapport

15.05.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 15.05.2024)

Information om virksomhedens regnskabsklasse:The annual report for MonTa Biosciences ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class B enterprises. The accounting policies are unchanged from last year, and the annual report is presented in DKK.

Beretning

15.05.2024

Dato for ledelsens godkendelse af årsrapporten:2024-05-13

Beskrivelse af usikkerhed ved indregning eller måling:Uncertainties about recognition or measurement The recognition of development projects is based on an assessment that the company's future expectations can be realised. The development projects have therefore not yet managed to generate positive cash flows in 2022, which increases the uncertainty regarding recognition and measurement of the intangible fixed assets. However, it is the management's assessment that the development projects will generate significant future income that can justify the accounting treatment and measurement of the development costs.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Managing Director have approved the annual report of MonTa Biosciences ApS for the financial year 1 January - 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:The principal activities of the company The object of the company is to develop novel oncology drugs using its proprietary drug delivery platform: immune stimulating compounds and formulations being mainly micelles carrrying TLR7 agonists for potential treatment of cancer. In the first project the company uses lipid micelles for delivery of a TLR7 agonist for potential treatment of cancer.